Can Hba1c be a marker for cardiovascular risk in type 2 Diabetes Mellitus
Abstract
Introduction: One in every five Indians in geriatric age has diabetes. Diabetes is associated with increase in TG and apo B, with decrease in HDL component, so it contributes to atherosclerosis formation. We conducted a study to correlate glycaemic control using glycated haemoglobin with dyslipidaemia.
Methods: The study is a cross sectional study with 200 diabetic patients, HbA1c was correlated with lipid profile and atherogenic index of plasma (AIP). AIP is log ratio of plasma triglyceride to HDL. Patients were categorised into good glycaemic control (<7%) and poor glycaemic control (>7%) based on glycaemic control with HbA1C as the marker.
Results: Study showed the duration of diabetes directly correlates with HbA1c. None of the patients who had diabetes for more than 10 had HbA1c less than seven. BMI had direct association with HbA1c. HbA1c demonstrated a positive significant correlation with Total Cholesterol, LDL and a negative significant correlation with HDL. Atherogenic index of plasma directly correlates with HbA1c with mean AIP of 0.36+0.24 and 0.58+18 in good glycaemic control (GCC) and poor glycaemic control (PCC) respectively. Patients with HbA1c >7.0% had statistically significantly higher value of total cholesterol, LDL when compared with <7.0%.
Conclusion: These findings clearly indicate that HbA1c can provide valuable supplementary information about the extent of dyslipidaemia, AIP. Screening for HbA1c estimation helps in preventing complications by achieving adequate glycaemic control. Thus, HbA1c can be used as a potential biomarker to identify patients with cardiovascular risk in Type 2 Diabetes Mellitus and can used as a guide for aggressive therapeutic approach.
Downloads
References
2. Chromium picolinate and biotin combination reduces atherogenic index of plasma in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomizedclinical trial. Geohas J et al. Am J Med Sci. 2007 Mar;333(3):145-153. [PubMed]
3. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, May 16, 2001.Vol 285, No. 19:2486-2497. [PubMed]
4. Whiting DR et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011 Dec;94(3):311-321. [PubMed]
5. Ronald K. Hyperglycemia and Microvascular and Macrovascular Disease in Diabetes, Diabetes Care, 1995; 18(2): 258-268. [PubMed]
6. Irene M S, Amanda I A, Andrew W N, David R M, Susan EM et al, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study, BMJ , 2000;321:405–412.
7. Chintamani Bodhe, Deepali Jankar, Tara Bhutada et al. HbA1c: predictor of dyslipidemia and atherogenicity in diabetes mellitus. International Journal of Basic Medical Science - November 2011;2(5): 278-282.
8. Fonseca VA. Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease. Am J Cardiol. 2003 Aug 18;92(4A):50J-60J. [PubMed]
9. Schwenke DC, D’Agostino RB Jr, Goff DC Jr, Karter AJ, Rewers MJ, Wagenknecht LE. Differences in LDL oxidizability by glycemic status: the insulin resistance atherosclerosis study. Diabetes Care. 2003 May;26(5):1449-55.
10. Campos H, Arnold KS, Balestra ME, Innerarity TL, Krauss RM: Differences in receptor binding of LDL subfractions. Arterioscler Thromb Vasc Biol. 1996 Jun;16(6):794-801. [PubMed]
11. Bjornheden T, Babyi A, Bondjers G, Wiklund O. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis. 1996 Jun;123(1-2):43-56. [PubMed]
12. Joslin‟s Diabetes Mellitus 14th Ed. Lippincott Williams & Wilkins Chapter 33: Pathophysiology and treatment of lipid disorders in diabetes, pp. 567-571. [PubMed]
13. Ahmad Khan H. Clinical significance of HbA1c as a marker of circulating lipids in male and female type 2 diabetic patients. Acta Diabetol. 2007 Dec;44(4):193-200. Epub 2007 Sep 1. [PubMed]
14. Ram Vinod Mahato. Association between glycaemic control and serum lipid profile in type 2 diabetic patients: Glycated haemoglobin as a dual biomarker. Biomedical Research, 2011, pp. 375-380. [PubMed]
15. H.O. Otamere, C.P Aloamaka, PO.Okokhere , W.A. Adisa. Lipid Profile in Diabetes Mellitus; What Impact Has Age and Duration. Br. J. Pharmacol. Toxicol. 2011; 2(3): 135-137.
16. Amy SS, Lawrence M D, Thomas R K, Zhiqian G, Philip R K, Stephen R D, Elaine MU, Influence of Duration of Diabetes, Glycemic Control, and Traditional Cardiovascular Risk Factors on Early Atherosclerotic Vascular Changes in Adolescents and Young Adults with Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2009; 94: 3740–3745.
17. Dobiasova M, Frohlich J, The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL), Clin Biochem, 2001; 34(7): 583-588. [PubMed]
18. Executive Summary of the 2014 American Diabetes Association Clinical Practice Recommendations (Diabetes Care 2014;37, suppl.1: S5-13.
OAI - Open Archives Initiative
